25 XP   0   0   10

Theravance Biopharma Inc
Buy, Hold or Sell?

Let's analyse Theravance together

PenkeI guess you are interested in Theravance Biopharma Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Theravance Biopharma Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Theravance Biopharma Inc

I send you an email if I find something interesting about Theravance Biopharma Inc.

Quick analysis of Theravance (30 sec.)










What can you expect buying and holding a share of Theravance? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
10.0%

What is your share worth?

Current worth
$4.31
Expected worth in 1 year
$2.07
How sure are you?
30.0%

+ What do you gain per year?

Total Gains per Share
$-2.25
Return On Investment
-25.0%

For what price can you sell your share?

Current Price per Share
$8.97
Expected price per share
$8.15 - $10.11
How sure are you?
50%

1. Valuation of Theravance (5 min.)




Live pricePrice per Share (EOD)

$8.97

Intrinsic Value Per Share

$-12.62 - $38.48

Total Value Per Share

$-8.31 - $42.79

2. Growth of Theravance (5 min.)




Is Theravance growing?

Current yearPrevious yearGrowGrow %
How rich?$212.9m$55.2m$222.1m80.1%

How much money is Theravance making?

Current yearPrevious yearGrowGrow %
Making money-$13.7m$217m-$230.8m-1,673.1%
Net Profit Margin-107.8%1,748.5%--

How much money comes from the company's main activities?

3. Financial Health of Theravance (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#247 / 1031

Most Revenue
#253 / 1031

Most Profit
#653 / 1031

Most Efficient
#601 / 1031

What can you expect buying and holding a share of Theravance? (5 min.)

Welcome investor! Theravance's management wants to use your money to grow the business. In return you get a share of Theravance.

What can you expect buying and holding a share of Theravance?

First you should know what it really means to hold a share of Theravance. And how you can make/lose money.

Speculation

The Price per Share of Theravance is $8.97. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Theravance.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Theravance, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $4.31. Based on the TTM, the Book Value Change Per Share is $-0.56 per quarter. Based on the YOY, the Book Value Change Per Share is $2.78 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Theravance.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.17-1.9%-0.24-2.7%2.8832.1%-0.06-0.6%-0.58-6.5%
Usd Book Value Change Per Share-0.39-4.4%-0.56-6.3%2.7831.0%0.262.9%0.121.3%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.707.8%0.353.9%
Usd Total Gains Per Share-0.39-4.4%-0.56-6.3%2.7931.1%0.9710.8%0.475.2%
Usd Price Per Share11.24-10.27-10.00-14.77-19.42-
Price to Earnings Ratio-16.31--11.51--11.51--7.43--6.53-
Price-to-Total Gains Ratio-28.80--22.91-15.20--7.84--49.01-
Price to Book Ratio2.61-2.10--0.18--2.79--2.07-
Price-to-Total Gains Ratio-28.80--22.91-15.20--7.84--49.01-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share8.97
Number of shares111
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.70
Usd Book Value Change Per Share-0.560.26
Usd Total Gains Per Share-0.560.97
Gains per Quarter (111 shares)-62.30107.33
Gains per Year (111 shares)-249.20429.31
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-249-259313117419
20-498-508625233848
30-748-7579383501277
40-997-100612514671706
50-1246-125515635832135
60-1495-150418767002564
70-1744-175321888172993
80-1994-200225019333422
90-2243-2251281410503851
100-2492-2500312611674280

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%1.043.01.02.2%
Book Value Change Per Share0.04.00.00.0%5.07.00.041.7%6.014.00.030.0%10.030.00.025.0%11.034.00.024.4%
Dividend per Share0.00.04.00.0%2.00.010.016.7%4.00.016.020.0%4.00.036.010.0%4.00.041.08.9%
Total Gains per Share0.04.00.00.0%6.06.00.050.0%8.012.00.040.0%12.028.00.030.0%13.032.00.028.9%

Fundamentals of Theravance

About Theravance Biopharma Inc

Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States and Europe. It offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD). The company's product includes Ampreloxetine, an investigational norepinephrine reuptake inhibitor that has completed Phase III study for neurogenic orthostatic hypotension; and TRELEGY for the treatment of COPD and asthma. It has licensing and collaboration agreements with Pfizer Inc. for its preclinical skin-selective pan-JAK inhibitor program, as well as Viatris Inc. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-03-22 05:16:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Theravance Biopharma Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Theravance earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • A Net Profit Margin of -48.5% means that $-0.48 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Theravance Biopharma Inc:

  • The MRQ is -48.5%. The company is making a huge loss. -2
  • The TTM is -107.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-48.5%TTM-107.8%+59.4%
TTM-107.8%YOY1,748.5%-1,856.3%
TTM-107.8%5Y67.9%-175.8%
5Y67.9%10Y-661.3%+729.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-48.5%-159.2%+110.7%
TTM-107.8%-202.3%+94.5%
YOY1,748.5%-263.0%+2,011.5%
5Y67.9%-452.4%+520.3%
10Y-661.3%-589.0%-72.3%
1.1.2. Return on Assets

Shows how efficient Theravance is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • -2.2% Return on Assets means that Theravance generated $-0.02 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Theravance Biopharma Inc:

  • The MRQ is -2.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-2.2%TTM-3.0%+0.8%
TTM-3.0%YOY27.0%-30.0%
TTM-3.0%5Y-2.9%-0.1%
5Y-2.9%10Y-13.7%+10.8%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.2%-12.5%+10.3%
TTM-3.0%-12.2%+9.2%
YOY27.0%-11.2%+38.2%
5Y-2.9%-13.3%+10.4%
10Y-13.7%-14.6%+0.9%
1.1.3. Return on Equity

Shows how efficient Theravance is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • -4.0% Return on Equity means Theravance generated $-0.04 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Theravance Biopharma Inc:

  • The MRQ is -4.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.8%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-4.0%TTM-4.8%+0.8%
TTM-4.8%YOY46.9%-51.7%
TTM-4.8%5Y8.4%-13.2%
5Y8.4%10Y-10.1%+18.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-4.0%-16.0%+12.0%
TTM-4.8%-15.8%+11.0%
YOY46.9%-13.9%+60.8%
5Y8.4%-18.2%+26.6%
10Y-10.1%-19.1%+9.0%

1.2. Operating Efficiency of Theravance Biopharma Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Theravance is operating .

  • Measures how much profit Theravance makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • An Operating Margin of -27.0% means the company generated $-0.27  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Theravance Biopharma Inc:

  • The MRQ is -27.0%. The company is operating very inefficient. -2
  • The TTM is -109.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-27.0%TTM-109.8%+82.8%
TTM-109.8%YOY-115.7%+5.9%
TTM-109.8%5Y-264.7%+154.9%
5Y-264.7%10Y-811.6%+547.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-27.0%-299.5%+272.5%
TTM-109.8%-208.5%+98.7%
YOY-115.7%-280.2%+164.5%
5Y-264.7%-459.9%+195.2%
10Y-811.6%-596.9%-214.7%
1.2.2. Operating Ratio

Measures how efficient Theravance is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 1.60 means that the operating costs are $1.60 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Theravance Biopharma Inc:

  • The MRQ is 1.602. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.207. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.602TTM2.207-0.605
TTM2.207YOY2.751-0.544
TTM2.2075Y4.552-2.344
5Y4.55210Y9.652-5.101
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.6022.817-1.215
TTM2.2073.181-0.974
YOY2.7513.609-0.858
5Y4.5525.554-1.002
10Y9.6527.396+2.256

1.3. Liquidity of Theravance Biopharma Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Theravance is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 5.39 means the company has $5.39 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Theravance Biopharma Inc:

  • The MRQ is 5.392. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.392. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ5.392TTM7.392-2.000
TTM7.392YOY6.321+1.072
TTM7.3925Y5.194+2.198
5Y5.19410Y6.036-0.842
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.3923.987+1.405
TTM7.3924.440+2.952
YOY6.3215.569+0.752
5Y5.1946.158-0.964
10Y6.0366.492-0.456
1.3.2. Quick Ratio

Measures if Theravance is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • A Quick Ratio of 7.38 means the company can pay off $7.38 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Theravance Biopharma Inc:

  • The MRQ is 7.380. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.885. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ7.380TTM10.885-3.505
TTM10.885YOY7.122+3.763
TTM10.8855Y6.993+3.892
5Y6.99310Y8.201-1.208
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.3803.653+3.727
TTM10.8854.158+6.727
YOY7.1225.515+1.607
5Y6.9936.012+0.981
10Y8.2016.206+1.995

1.4. Solvency of Theravance Biopharma Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Theravance assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Theravance to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.44 means that Theravance assets are financed with 44.2% credit (debt) and the remaining percentage (100% - 44.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Theravance Biopharma Inc:

  • The MRQ is 0.442. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.383. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.442TTM0.383+0.059
TTM0.383YOY1.150-0.767
TTM0.3835Y1.238-0.855
5Y1.23810Y0.866+0.372
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4420.336+0.106
TTM0.3830.330+0.053
YOY1.1500.267+0.883
5Y1.2380.367+0.871
10Y0.8660.378+0.488
1.4.2. Debt to Equity Ratio

Measures if Theravance is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Theravance to the Biotechnology industry mean.
  • A Debt to Equity ratio of 79.3% means that company has $0.79 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Theravance Biopharma Inc:

  • The MRQ is 0.793. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.630. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.793TTM0.630+0.163
TTM0.630YOY0.241+0.389
TTM0.6305Y0.174+0.456
5Y0.17410Y0.763-0.588
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7930.376+0.417
TTM0.6300.398+0.232
YOY0.2410.334-0.093
5Y0.1740.431-0.257
10Y0.7630.476+0.287

2. Market Valuation of Theravance Biopharma Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Theravance generates.

  • Above 15 is considered overpriced but always compare Theravance to the Biotechnology industry mean.
  • A PE ratio of -16.31 means the investor is paying $-16.31 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Theravance Biopharma Inc:

  • The EOD is -13.020. Based on the earnings, the company is expensive. -2
  • The MRQ is -16.315. Based on the earnings, the company is expensive. -2
  • The TTM is -11.510. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-13.020MRQ-16.315+3.295
MRQ-16.315TTM-11.510-4.805
TTM-11.510YOY-11.514+0.004
TTM-11.5105Y-7.429-4.081
5Y-7.42910Y-6.532-0.897
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-13.020-2.697-10.323
MRQ-16.315-2.422-13.893
TTM-11.510-2.709-8.801
YOY-11.514-4.116-7.398
5Y-7.429-6.257-1.172
10Y-6.532-6.478-0.054
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Theravance Biopharma Inc:

  • The EOD is -72.380. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -90.696. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -40.209. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-72.380MRQ-90.696+18.317
MRQ-90.696TTM-40.209-50.488
TTM-40.209YOY-7.160-33.049
TTM-40.2095Y-12.292-27.916
5Y-12.29210Y-9.895-2.397
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-72.380-3.344-69.036
MRQ-90.696-2.939-87.757
TTM-40.209-3.486-36.723
YOY-7.160-5.592-1.568
5Y-12.292-8.464-3.828
10Y-9.895-8.872-1.023
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Theravance is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.61 means the investor is paying $2.61 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Theravance Biopharma Inc:

  • The EOD is 2.081. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.608. Based on the equity, the company is underpriced. +1
  • The TTM is 2.095. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD2.081MRQ2.608-0.527
MRQ2.608TTM2.095+0.513
TTM2.095YOY-0.179+2.274
TTM2.0955Y-2.785+4.881
5Y-2.78510Y-2.070-0.716
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0812.198-0.117
MRQ2.6082.042+0.566
TTM2.0952.121-0.026
YOY-0.1792.907-3.086
5Y-2.7853.682-6.467
10Y-2.0704.114-6.184
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Theravance Biopharma Inc.

3.1. Institutions holding Theravance Biopharma Inc

Institutions are holding 104.244% of the shares of Theravance Biopharma Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Weiss Asset Management LP15.50614.0036745706000
2023-12-31Baupost Group LLC15.42751.8188741922600
2023-12-31Madison Avenue Partners, LP14.581211.1281701222600
2023-12-31BlackRock Inc9.53990.00134587834209040.4577
2023-12-31Vanguard Group Inc7.25550.00093489262-350067-9.1179
2023-12-31Irenic Capital Management LP5.74116.15276094800
2023-12-31Pictet Asset Manangement SA4.50890.026921683971601447.9743
2023-12-31Newtyn Management LLC3.95084.19231900000584403.1734
2023-12-31State Street Corporation2.8910.00081390314-80873-5.4971
2023-12-31Oasis Management Co. Ltd2.09372.08411006858536045.6233
2023-12-31Geode Capital Management, LLC2.06690.0012994000-67177-6.3304
2023-12-31Park West Asset Management LLC1.87150.991900000-1083251-54.62
2023-09-30D. E. Shaw & Co LP1.43390.0062689561-24553-3.4382
2023-12-31Goldman Sachs Group Inc1.19060.0006572582302797112.2364
2023-12-31Bank of America Corp1.16970.0006562534-13024-2.2628
2023-12-31Northern Trust Corp1.08530.0011521936-34459-6.1933
2023-09-30JANE STREET GROUP, LLC0.95550.0013459511330917.7602
2023-09-30Jacobs Levy Equity Management, Inc.0.84740.0208407525-190039-31.8023
2023-12-31Charles Schwab Investment Management Inc0.6530.0009314011-14166-4.3166
2023-09-30Chescapmanager LLC0.59750.315928733300
Total 93.36730.746444901118-1228629-2.7%

3.2. Funds holding Theravance Biopharma Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29iShares Russell 2000 ETF2.55720.01871229766-201-0.0163
2024-02-29Vanguard Total Stock Mkt Idx Inv2.23160.00071073178-153815-12.5359
2023-10-13Pictet Biopharmaceutical Mother2.1280.6449102340029124139.7784
2024-02-29Vanguard Small Cap Index1.73510.005683441076870.9298
2023-12-31Fidelity Small Cap Index1.06190.0226510663-44263-7.9764
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.0270.0046493889-363-0.0734
2024-02-01iShares Russell 2000 Value ETF1.00140.03734815746100.1268
2024-02-29Vanguard Small Cap Growth Index Inv0.97390.012746835877401.6804
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.74330.008135748312000.3368
2024-02-29iShares Biotechnology ETF0.7310.0438351542-1580-0.4474
2024-01-31Delaware Healthcare I0.43410.269320878300
2024-01-31Fidelity Extended Market Index0.39490.00518992600
2024-02-29Vanguard Russell 2000 ETF0.38950.0186187320145968.4505
2024-02-29State St Russell Sm Cap® Indx SL Cl I0.37470.018118019700
2024-02-29Schwab US Small-Cap ETF™0.33850.009316279100
2023-12-31NT R2000 Value Index Fund - NL0.30140.0431144941-18108-11.1059
2023-12-31NT R2000 Index Fund - NL0.29930.0223143914-17767-10.9889
2024-02-29Vanguard Health Care ETF0.26460.0058127249-14679-10.3426
2024-01-31Schwab Small Cap Index0.24820.019911937300
2024-02-29iShares Micro-Cap ETF0.23960.119711521400
Total 17.47521.33018403971+72298+0.9%

3.3. Insider Transactions

Insiders are holding 5.179% of the shares of Theravance Biopharma Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-02-22Rhonda FarnumSELL12548.71
2023-11-21Rhonda FarnumSELL137810.29
2023-11-14Richard A GrahamSELL248210.22
2023-10-16Richard A GrahamSELL24829.03
2023-09-14Richard A GrahamSELL24829.89
2023-08-22Rhonda FarnumSELL18079.47
2023-08-11Richard A GrahamSELL23229.99
2023-07-14Richard A GrahamSELL23229.84
2023-06-14Richard A GrahamSELL232210.69
2023-06-08Rhonda FarnumSELL179011.13
2023-05-15Richard A GrahamSELL232211.26
2023-04-14Richard A GrahamSELL232311.88

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Theravance Biopharma Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.390-0.561+44%2.783-114%0.263-249%0.117-435%
Book Value Per Share--4.3104.960-13%0.916+371%-1.120+126%1.520+184%
Current Ratio--5.3927.392-27%6.321-15%5.194+4%6.036-11%
Debt To Asset Ratio--0.4420.383+16%1.150-62%1.238-64%0.866-49%
Debt To Equity Ratio--0.7930.630+26%0.241+229%0.174+355%0.763+4%
Dividend Per Share----0%0.003-100%0.704-100%0.352-100%
Eps---0.172-0.243+41%2.883-106%-0.056-68%-0.580+237%
Free Cash Flow Per Share---0.031-0.127+309%-0.671+2064%-0.737+2279%-0.754+2335%
Free Cash Flow To Equity Per Share---0.650-1.011+55%-3.197+392%-1.127+73%-0.367-44%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--38.482--------
Intrinsic Value_10Y_min---12.617--------
Intrinsic Value_1Y_max---1.233--------
Intrinsic Value_1Y_min---2.737--------
Intrinsic Value_3Y_max--0.174--------
Intrinsic Value_3Y_min---6.997--------
Intrinsic Value_5Y_max--6.257--------
Intrinsic Value_5Y_min---9.879--------
Market Cap432037359.000-29%555424600.000569198157.500-2%733065380.000-24%914768691.750-39%1067616727.900-48%
Net Profit Margin---0.485-1.078+123%17.485-103%0.679-171%-6.613+1265%
Operating Margin---0.270-1.098+306%-1.157+328%-2.647+879%-8.116+2901%
Operating Ratio--1.6022.207-27%2.751-42%4.552-65%9.652-83%
Pb Ratio2.081-25%2.6082.095+24%-0.179+107%-2.785+207%-2.070+179%
Pe Ratio-13.020+20%-16.315-11.510-29%-11.514-29%-7.429-54%-6.532-60%
Price Per Share8.970-25%11.24010.268+9%9.995+12%14.773-24%19.416-42%
Price To Free Cash Flow Ratio-72.380+20%-90.696-40.209-56%-7.160-92%-12.292-86%-9.895-89%
Price To Total Gains Ratio-22.982+20%-28.798-22.915-20%15.198-289%-7.845-73%-49.006+70%
Quick Ratio--7.38010.885-32%7.122+4%6.993+6%8.201-10%
Return On Assets---0.022-0.030+35%0.270-108%-0.029+28%-0.137+515%
Return On Equity---0.040-0.048+20%0.469-109%0.084-147%-0.101+153%
Total Gains Per Share---0.390-0.561+44%2.786-114%0.967-140%0.469-183%
Usd Book Value--212995000.000277461250.000-23%55279750.000+285%-79373650.000+137%62418250.000+241%
Usd Book Value Change Per Share---0.390-0.561+44%2.783-114%0.263-249%0.117-435%
Usd Book Value Per Share--4.3104.960-13%0.916+371%-1.120+126%1.520+184%
Usd Dividend Per Share----0%0.003-100%0.704-100%0.352-100%
Usd Eps---0.172-0.243+41%2.883-106%-0.056-68%-0.580+237%
Usd Free Cash Flow---1531000.000-7371250.000+381%-46905024.000+2964%-46338054.800+2927%-42530402.400+2678%
Usd Free Cash Flow Per Share---0.031-0.127+309%-0.671+2064%-0.737+2279%-0.754+2335%
Usd Free Cash Flow To Equity Per Share---0.650-1.011+55%-3.197+392%-1.127+73%-0.367-44%
Usd Market Cap432037359.000-29%555424600.000569198157.500-2%733065380.000-24%914768691.750-39%1067616727.900-48%
Usd Price Per Share8.970-25%11.24010.268+9%9.995+12%14.773-24%19.416-42%
Usd Profit---8511000.000-13798500.000+62%217059000.000-104%4957150.000-272%-25292750.000+197%
Usd Revenue--17565000.00014356000.000+22%12836500.000+37%15467550.000+14%12189225.000+44%
Usd Total Gains Per Share---0.390-0.561+44%2.786-114%0.967-140%0.469-183%
 EOD+3 -5MRQTTM+21 -12YOY+16 -195Y+18 -1710Y+20 -15

4.2. Fundamental Score

Let's check the fundamental score of Theravance Biopharma Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-13.020
Price to Book Ratio (EOD)Between0-12.081
Net Profit Margin (MRQ)Greater than0-0.485
Operating Margin (MRQ)Greater than0-0.270
Quick Ratio (MRQ)Greater than17.380
Current Ratio (MRQ)Greater than15.392
Debt to Asset Ratio (MRQ)Less than10.442
Debt to Equity Ratio (MRQ)Less than10.793
Return on Equity (MRQ)Greater than0.15-0.040
Return on Assets (MRQ)Greater than0.05-0.022
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Theravance Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.472
Ma 20Greater thanMa 508.818
Ma 50Greater thanMa 1009.017
Ma 100Greater thanMa 2009.793
OpenGreater thanClose9.000
Total3/5 (60.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Current Deferred Revenue 24024024024-5,471-5,447



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets381,999
Total Liabilities169,004
Total Stockholder Equity212,995
 As reported
Total Liabilities 169,004
Total Stockholder Equity+ 212,995
Total Assets = 381,999

Assets

Total Assets381,999
Total Current Assets133,541
Long-term Assets248,458
Total Current Assets
Cash And Cash Equivalents 39,545
Short-term Investments 62,881
Net Receivables 17,474
Other Current Assets 13,641
Total Current Assets  (as reported)133,541
Total Current Assets  (calculated)133,541
+/-0
Long-term Assets
Property Plant Equipment 45,355
Long-term Assets Other 202,267
Long-term Assets  (as reported)248,458
Long-term Assets  (calculated)247,622
+/- 836

Liabilities & Shareholders' Equity

Total Current Liabilities24,767
Long-term Liabilities144,237
Total Stockholder Equity212,995
Total Current Liabilities
Short-term Debt 3,923
Accounts payable 1,524
Other Current Liabilities 24,767
Total Current Liabilities  (as reported)24,767
Total Current Liabilities  (calculated)30,214
+/- 5,447
Long-term Liabilities
Capital Lease Obligations 49,159
Long-term Liabilities Other 33,707
Long-term Liabilities  (as reported)144,237
Long-term Liabilities  (calculated)82,866
+/- 61,371
Total Stockholder Equity
Retained Earnings -909,104
Accumulated Other Comprehensive Income -65
Other Stockholders Equity 1,122,164
Total Stockholder Equity (as reported)212,995
Total Stockholder Equity (calculated)212,995
+/-0
Other
Cash and Short Term Investments 102,426
Common Stock Shares Outstanding 49,415
Current Deferred Revenue-5,447
Liabilities and Stockholders Equity 381,999
Net Debt 5,691
Net Invested Capital 212,995
Net Working Capital 108,774
Property Plant and Equipment Gross 66,937
Short Long Term Debt Total 45,236



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-31
> Total Assets 
20,962
23,530
22,306
23,600
25,177
26,167
430,588
381,705
337,771
324,901
289,479
257,506
300,116
293,125
374,488
356,289
639,254
588,039
543,886
486,159
441,400
480,108
421,364
370,964
560,235
531,265
492,447
445,337
408,826
605,409
564,330
512,188
469,057
375,108
429,251
403,109
374,819
355,359
360,761
763,496
607,400
538,550
446,630
413,590
381,999
381,999413,590446,630538,550607,400763,496360,761355,359374,819403,109429,251375,108469,057512,188564,330605,409408,826445,337492,447531,265560,235370,964421,364480,108441,400486,159543,886588,039639,254356,289374,488293,125300,116257,506289,479324,901337,771381,705430,58826,16725,17723,60022,30623,53020,962
   > Total Current Assets 
0
0
0
14,200
14,106
15,600
420,964
372,349
326,769
275,556
260,226
238,239
237,472
238,752
303,125
274,035
528,503
421,504
384,882
367,133
378,749
446,818
386,693
332,606
532,823
467,233
426,038
355,652
338,488
534,218
498,386
450,724
393,341
293,071
333,180
297,172
249,870
204,636
154,729
511,718
353,464
261,338
192,003
161,690
133,541
133,541161,690192,003261,338353,464511,718154,729204,636249,870297,172333,180293,071393,341450,724498,386534,218338,488355,652426,038467,233532,823332,606386,693446,818378,749367,133384,882421,504528,503274,035303,125238,752237,472238,239260,226275,556326,769372,349420,96415,60014,10614,200000
       Cash And Cash Equivalents 
0
0
0
0
89,000
833
268,199
122,228
89,215
100,899
97,090
127,114
112,707
128,803
148,363
86,572
344,709
169,945
139,626
91,301
88,980
125,831
103,854
101,202
378,021
223,235
178,311
102,403
58,064
332,798
104,735
93,282
81,467
114,011
204,949
121,424
89,959
94,367
87,292
418,538
298,172
187,665
-42,521
71,685
39,545
39,54571,685-42,521187,665298,172418,53887,29294,36789,959121,424204,949114,01181,46793,282104,735332,79858,064102,403178,311223,235378,021101,202103,854125,83188,98091,301139,626169,945344,70986,572148,363128,803112,707127,11497,090100,89989,215122,228268,19983389,0000000
       Short-term Investments 
0
0
0
0
165,000
0
80,997
162,489
165,396
135,337
113,896
68,856
59,727
51,073
101,316
143,910
156,387
222,823
222,194
243,700
259,586
292,700
249,049
199,207
127,255
210,823
217,761
217,278
222,767
154,233
333,605
265,065
211,474
95,957
60,004
94,789
83,506
53,149
45,558
68,294
29,312
53,598
209,972
62,318
62,881
62,88162,318209,97253,59829,31268,29445,55853,14983,50694,78960,00495,957211,474265,065333,605154,233222,767217,278217,761210,823127,255199,207249,049292,700259,586243,700222,194222,823156,387143,910101,31651,07359,72768,856113,896135,337165,396162,48980,9970165,0000000
       Net Receivables 
0
0
0
2,600
1,133
93
15,243
411
2,129
20,225
26,293
20,423
37,154
39,063
36,936
22,713
9,076
8,872
5,318
11,547
7,109
4,818
3,865
3,907
10,053
7,824
979
21,256
50,570
41,696
46,922
61,308
69,667
54,274
39,961
57,774
57,599
47,836
12,488
14,114
16,785
12,270
15,796
17,057
17,474
17,47417,05715,79612,27016,78514,11412,48847,83657,59957,77439,96154,27469,66761,30846,92241,69650,57021,2569797,82410,0533,9073,8654,8187,10911,5475,3188,8729,07622,71336,93639,06337,15420,42326,29320,2252,12941115,243931,1332,600000
       Other Current Assets 
2,280
3,535
2,245
2,600
2,567
4,493
3,538
6,865
8,213
6,758
10,394
9,705
5,115
10,165
3,550
5,192
3,051
3,566
5,376
5,038
5,953
5,326
11,075
10,053
17,494
25,351
28,987
7,219
7,087
5,491
13,124
10,308
10,359
10,037
12,353
9,943
8,561
9,284
9,391
79,066
7,682
6,281
7,777
8,996
13,641
13,6418,9967,7776,2817,68279,0669,3919,2848,5619,94312,35310,03710,35910,30813,1245,4917,0877,21928,98725,35117,49410,05311,0755,3265,9535,0385,3763,5663,0515,1923,55010,1655,1159,70510,3946,7588,2136,8653,5384,4932,5672,6002,2453,5352,280
   > Long-term Assets 
0
0
0
9,400
11,071
10,567
9,624
9,356
11,002
49,345
29,253
19,267
62,644
54,373
71,363
82,254
110,751
166,535
159,004
119,026
62,651
33,290
34,671
38,358
27,412
64,032
66,409
89,685
70,338
71,191
65,944
61,464
75,716
82,037
96,071
105,937
124,949
150,723
206,032
251,778
253,936
277,212
254,627
251,900
248,458
248,458251,900254,627277,212253,936251,778206,032150,723124,949105,93796,07182,03775,71661,46465,94471,19170,33889,68566,40964,03227,41238,35834,67133,29062,651119,026159,004166,535110,75182,25471,36354,37362,64419,26729,25349,34511,0029,3569,62410,56711,0719,400000
       Property Plant Equipment 
9,154
9,010
8,952
8,600
10,238
9,734
9,624
9,356
9,663
9,305
9,609
9,513
9,873
10,119
8,811
8,832
8,460
8,251
8,679
8,618
10,157
10,329
10,677
12,415
13,176
61,760
60,493
58,944
59,248
60,011
59,617
59,821
59,682
59,461
58,091
56,721
53,347
52,585
53,643
51,876
52,001
51,307
48,006
46,864
45,355
45,35546,86448,00651,30752,00151,87653,64352,58553,34756,72158,09159,46159,68259,82159,61760,01159,24858,94460,49361,76013,17612,41510,67710,32910,1578,6188,6798,2518,4608,8328,81110,1199,8739,5139,6099,3059,6639,3569,6249,73410,2388,6008,9529,0109,154
       Long Term Investments 
0
0
0
0
51,000
0
38,231
65,638
51,399
38,521
17,794
8,000
50,860
42,598
60,316
66,769
99,565
155,885
144,445
107,469
49,778
20,323
21,395
23,348
11,869
0
3,695
28,603
8,667
9,039
3,986
0
12,750
19,439
35,822
45,086
67,537
94,108
148,250
0
0
18,776
0
0
0
00018,77600148,25094,10867,53745,08635,82219,43912,75003,9869,0398,66728,6033,695011,86923,34821,39520,32349,778107,469144,445155,88599,56566,76960,31642,59850,8608,00017,79438,52151,39965,63838,231051,0000000
       Long-term Assets Other 
0
0
0
800
833
833
-38,231
-65,638
-50,060
1,519
1,850
1,754
1,911
1,656
2,236
14,653
10,726
2,399
13,880
11,009
10,907
5,962
5,742
5,726
2,367
2,272
5,916
5,802
6,105
6,113
6,327
1,643
3,284
3,137
2,158
4,130
4,065
4,030
4,139
199,066
201,099
207,129
205,785
204,200
202,267
202,267204,200205,785207,129201,099199,0664,1394,0304,0654,1302,1583,1373,2841,6436,3276,1136,1055,8025,9162,2722,3675,7265,7425,96210,90711,00913,8802,39910,72614,6532,2361,6561,9111,7541,8501,519-50,060-65,638-38,231833833800000
> Total Liabilities 
27,952
27,905
34,362
38,000
42,212
44,083
45,829
41,884
47,984
35,786
31,805
34,961
57,051
54,588
52,904
58,416
289,023
294,093
302,759
302,042
326,222
416,701
386,977
384,409
611,824
644,517
629,671
628,142
632,666
763,345
766,666
773,724
772,808
748,326
729,625
726,701
713,392
706,809
710,570
282,918
165,600
167,991
166,469
167,460
169,004
169,004167,460166,469167,991165,600282,918710,570706,809713,392726,701729,625748,326772,808773,724766,666763,345632,666628,142629,671644,517611,824384,409386,977416,701326,222302,042302,759294,093289,02358,41652,90454,58857,05134,96131,80535,78647,98441,88445,82944,08342,21238,00034,36227,90527,952
   > Total Current Liabilities 
22,672
22,754
28,889
32,700
36,853
38,544
40,111
35,828
41,256
28,852
24,477
27,430
49,470
46,401
44,657
45,410
49,268
48,984
57,103
48,786
62,552
105,179
93,480
102,029
98,554
113,542
110,136
108,823
111,703
98,040
106,574
104,270
123,571
86,492
67,127
66,082
58,587
44,201
32,624
142,132
28,715
26,184
24,546
25,368
24,767
24,76725,36824,54626,18428,715142,13232,62444,20158,58766,08267,12786,492123,571104,270106,57498,040111,703108,823110,136113,54298,554102,02993,480105,17962,55248,78657,10348,98449,26845,41044,65746,40149,47027,43024,47728,85241,25635,82840,11138,54436,85332,70028,88922,75422,672
       Short-term Debt 
0
0
0
0
223,000
0
-15,222
5,216
223,000
0
0
0
223,000
0
223,000
223,000
222,676
222,942
223,210
223,478
223,746
224,014
224,282
0
0
8,300
20,235
15,534
17,613
7,954
8,741
9,685
29,201
12,879
7,978
13,546
17,443
13,066
2,624
692
28,715
7,431
9,160
9,713
3,923
3,9239,7139,1607,43128,7156922,62413,06617,44313,5467,97812,87929,2019,6858,7417,95417,61315,53420,2358,30000224,282224,014223,746223,478223,210222,942222,676223,000223,0000223,000000223,0005,216-15,2220223,0000000
       Short Long Term Debt 
0
0
0
0
223,000
0
0
0
223,000
0
0
0
223,000
0
223,000
223,000
222,676
222,942
223,210
223,478
223,746
224,014
224,282
0
0
8,300
12,348
8,701
9,851
0
0
0
19,334
11,659
6,941
12,530
16,940
9,012
0
0
0
0
0
0
0
00000009,01216,94012,5306,94111,65919,3340009,8518,70112,3488,30000224,282224,014223,746223,478223,210222,942222,676223,000223,0000223,000000223,000000223,0000000
       Accounts payable 
5,225
3,444
4,467
5,400
6,940
4,984
9,499
5,284
9,921
4,021
6,335
5,963
18,804
9,092
7,412
5,351
1,733
3,626
6,406
5,623
5,924
5,085
3,644
3,745
9,028
5,596
3,501
8,713
4,758
6,645
10,065
6,442
6,775
6,834
10,702
8,900
3,098
1,510
3,074
5,337
1,554
2,663
1,569
2,368
1,524
1,5242,3681,5692,6631,5545,3373,0741,5103,0988,90010,7026,8346,7756,44210,0656,6454,7588,7133,5015,5969,0283,7453,6445,0855,9245,6236,4063,6261,7335,3517,4129,09218,8045,9636,3354,0219,9215,2849,4994,9846,9405,4004,4673,4445,225
       Other Current Liabilities 
17,447
19,310
24,422
27,300
21,706
25,828
40,111
24,661
31,246
24,521
17,800
21,196
30,522
36,189
36,583
39,841
47,383
45,216
50,555
43,029
56,503
49,932
35,358
41,045
46,124
57,131
43,089
50,825
57,757
60,248
62,706
69,939
76,072
59,118
42,757
40,734
37,948
29,527
26,902
136,079
-1,578
16,066
13,793
13,263
24,767
24,76713,26313,79316,066-1,578136,07926,90229,52737,94840,73442,75759,11876,07269,93962,70660,24857,75750,82543,08957,13146,12441,04535,35849,93256,50343,02950,55545,21647,38339,84136,58336,18930,52221,19617,80024,52131,24624,66140,11125,82821,70627,30024,42219,31017,447
   > Long-term Liabilities 
0
0
0
5,300
5,359
5,539
5,718
6,056
6,728
6,934
7,328
7,531
7,581
8,187
8,247
13,006
239,755
245,109
245,656
253,256
263,670
311,522
293,497
282,380
513,270
530,975
519,535
519,319
520,963
665,305
660,092
669,454
649,237
661,834
662,498
660,619
654,805
662,608
677,946
140,786
136,885
141,807
141,923
142,092
144,237
144,237142,092141,923141,807136,885140,786677,946662,608654,805660,619662,498661,834649,237669,454660,092665,305520,963519,319519,535530,975513,270282,380293,497311,522263,670253,256245,656245,109239,75513,0068,2478,1877,5817,5317,3286,9346,7286,0565,7185,5395,3595,300000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
222,676
222,942
223,210
223,478
223,746
224,014
224,282
224,550
454,353
446,488
443,069
447,630
445,190
226,158
226,427
226,695
226,963
227,230
227,499
227,767
228,035
228,303
228,571
0
0
0
0
0
0
000000228,571228,303228,035227,767227,499227,230226,963226,695226,427226,158445,190447,630443,069446,488454,353224,550224,282224,014223,746223,478223,210222,942222,6760000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
-223,000
0
15,222
-5,216
-223,000
0
0
0
-223,000
0
-223,000
-223,000
-222,676
-222,942
-223,210
-223,478
-223,746
-224,014
-224,282
0
0
40,193
36,217
39,919
37,874
47,199
47,631
47,823
18,019
44,147
49,790
40,807
35,238
38,403
48,018
50,689
45,407
36,332
33,361
31,405
45,236
45,23631,40533,36136,33245,40750,68948,01838,40335,23840,80749,79044,14718,01947,82347,63147,19937,87439,91936,21740,19300-224,282-224,014-223,746-223,478-223,210-222,942-222,676-223,000-223,0000-223,000000-223,000-5,21615,2220-223,0000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
986
1,578
1,890
2,433
2,785
2,983
3,738
3,878
8,847
13,113
18,493
18,996
26,490
36,256
36,085
28,325
28,323
24,762
14,261
14,457
8,900
21,287
9,583
9,614
9,704
1,833
2,058
1,833
2,929
2,730
2,428
2,608
89,405
1,657
7,678
99,402
100,974
33,707
33,707100,97499,4027,6781,65789,4052,6082,4282,7302,9291,8332,0581,8339,7049,6149,58321,2878,90014,45714,26124,76228,32328,32536,08536,25626,49018,99618,49313,1138,8473,8783,7382,9832,7852,4331,8901,5789860000000
       Deferred Long Term Liability 
0
0
0
0
0
5,539
5,718
5,070
5,150
5,044
4,895
4,746
4,598
4,449
4,369
4,159
3,966
3,674
3,450
3,288
3,668
5,772
6,670
7,038
7,976
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000007,9767,0386,6705,7723,6683,2883,4503,6743,9664,1594,3694,4494,5984,7464,8955,0445,1505,0705,7185,53900000
> Total Stockholder Equity
0
0
0
-14,400
-17,035
-17,916
384,759
339,821
289,787
289,115
257,674
222,545
243,065
238,537
321,584
297,873
350,231
293,946
241,127
184,117
115,178
63,407
34,387
-13,445
-51,589
-113,252
-137,224
-182,805
-223,840
-157,936
-202,336
-261,536
-303,751
-373,218
-300,374
-323,592
-338,573
-351,450
-349,809
480,578
441,800
370,559
280,161
246,130
212,995
212,995246,130280,161370,559441,800480,578-349,809-351,450-338,573-323,592-300,374-373,218-303,751-261,536-202,336-157,936-223,840-182,805-137,224-113,252-51,589-13,44534,38763,407115,178184,117241,127293,946350,231297,873321,584238,537243,065222,545257,674289,115289,787339,821384,759-17,916-17,035-14,400000
   Common Stock
0
0
0
0
429,000
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
0
0111111111111111111111111111100000000000429,0000000
   Retained Earnings Total Equity00-891,644-875,999-853,911-843,549-1,760,180-1,751,989-1,726,043-1,694,009-1,658,701-1,606,296-1,526,617-1,468,183-1,394,540-1,331,653-1,248,600-1,182,994-1,124,563-1,084,725-1,012,145-961,959-902,526-861,708-797,740-710,818-643,941-577,654-512,225-444,892-410,931-363,706-321,556-276,730-229,415-181,811-139,337-75,027-20,532000000
   Accumulated Other Comprehensive Income 
0
0
0
-28,800
-34,000
-35,800
70
-27
-82
31
25
43
-70
126
181
39
-253
-272
-248
-292
-733
-854
-525
-331
-166
-36
129
94
145
512
280
122
47
17
8
14
0
-28
-45
-121
-15
51
-286
-225
-65
-65-225-28651-15-121-45-280148174712228051214594129-36-166-331-525-854-733-292-248-272-25339181126-70432531-82-2770-35,800-34,000-28,800000
   Capital Surplus 
0
0
0
0
0
0
405,221
414,875
429,206
470,895
487,064
499,232
564,691
602,117
732,334
742,726
862,708
871,871
885,315
895,226
913,650
925,968
937,437
948,844
960,721
971,508
987,209
1,000,094
1,024,614
1,173,204
1,191,923
1,206,524
1,222,818
1,233,060
1,358,318
1,370,402
1,387,469
1,400,566
1,410,415
1,324,247
1,295,725
1,246,506
1,172,090
0
0
001,172,0901,246,5061,295,7251,324,2471,410,4151,400,5661,387,4691,370,4021,358,3181,233,0601,222,8181,206,5241,191,9231,173,2041,024,6141,000,094987,209971,508960,721948,844937,437925,968913,650895,226885,315871,871862,708742,726732,334602,117564,691499,232487,064470,895429,206414,875405,221000000
   Treasury Stock000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
14,400
0
35,800
405,221
414,875
429,206
470,895
487,064
499,232
564,691
602,117
732,334
742,726
862,708
871,871
885,315
895,226
913,650
925,968
937,437
948,844
960,721
971,508
987,209
1,000,094
1,024,614
1,173,204
1,191,923
1,206,524
1,222,818
1,233,060
1,358,318
1,370,402
1,387,469
1,400,566
1,410,415
1,324,247
1,295,725
1,246,506
1,172,090
1,146,948
1,122,164
1,122,1641,146,9481,172,0901,246,5061,295,7251,324,2471,410,4151,400,5661,387,4691,370,4021,358,3181,233,0601,222,8181,206,5241,191,9231,173,2041,024,6141,000,094987,209971,508960,721948,844937,437925,968913,650895,226885,315871,871862,708742,726732,334602,117564,691499,232487,064470,895429,206414,875405,22135,800014,400000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue57,424
Cost of Revenue-6,052
Gross Profit51,37251,372
 
Operating Income (+$)
Gross Profit51,372
Operating Expense-110,716
Operating Income-53,292-59,344
 
Operating Expense (+$)
Research Development40,621
Selling General Administrative71,335
Selling And Marketing Expenses0
Operating Expense110,716111,956
 
Net Interest Income (+$)
Interest Income10,991
Interest Expense-2,350
Other Finance Cost-73
Net Interest Income8,714
 
Pretax Income (+$)
Operating Income-53,292
Net Interest Income8,714
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-49,269-57,315
EBIT - interestExpense = -46,883
-49,269
-52,843
Interest Expense2,350
Earnings Before Interest and Taxes (EBIT)-44,533-46,919
Earnings Before Interest and Taxes (EBITDA)-40,277
 
After tax Income (+$)
Income Before Tax-49,269
Tax Provision-2,427
Net Income From Continuing Ops-60,939-51,696
Net Income-55,193
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses110,716
Total Other Income/Expenses Net4,023-8,714
 

Technical Analysis of Theravance
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Theravance. The general trend of Theravance is BEARISH with 71.4% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Theravance's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-71.4%) Bearish trend (71.4%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Theravance Biopharma Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 9.255 < 10.07 < 10.11.

The bearish price targets are: 8.42 > 8.21 > 8.15.

Tweet this
Theravance Biopharma Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Theravance Biopharma Inc. The current mas is .

The long score for the Moving Averages is 2/14.
The longshort score for the Moving Averages is -10/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Theravance Biopharma Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Theravance Biopharma Inc. The current macd is -0.04020958.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Theravance price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Theravance. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Theravance price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Theravance Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) ChartTheravance Biopharma Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Theravance Biopharma Inc. The current adx is 19.47.

The long score for the Directional Movement Index (DMI) is 1/7.
The longshort score for the Directional Movement Index (DMI) is 1/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Theravance shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending down: The ADX is below 25 and indicates a weak or no trend. Also, the ADX is declining so there is no trend indication.
Theravance Biopharma Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Theravance Biopharma Inc. The current sar is 8.45940136.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Theravance Biopharma Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Theravance Biopharma Inc. The current rsi is 51.47. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Theravance Biopharma Inc Daily Relative Strength Index (RSI) ChartTheravance Biopharma Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Theravance Biopharma Inc. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Theravance price going up in the near term. +2
  • Trending down: The STOCH %K is trending down. -1
Theravance Biopharma Inc Daily Stochastic Oscillator ChartTheravance Biopharma Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Theravance Biopharma Inc. The current cci is 36.47.

Theravance Biopharma Inc Daily Commodity Channel Index (CCI) ChartTheravance Biopharma Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Theravance Biopharma Inc. The current cmo is 10.46.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Theravance Biopharma Inc Daily Chande Momentum Oscillator (CMO) ChartTheravance Biopharma Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Theravance Biopharma Inc. The current willr is -34.13173653.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Theravance is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Theravance Biopharma Inc Daily Williams %R ChartTheravance Biopharma Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Theravance Biopharma Inc.

Theravance Biopharma Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Theravance Biopharma Inc. The current atr is 0.31617092.

Theravance Biopharma Inc Daily Average True Range (ATR) ChartTheravance Biopharma Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Theravance Biopharma Inc. The current obv is -12,244,486.

Theravance Biopharma Inc Daily On-Balance Volume (OBV) ChartTheravance Biopharma Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Theravance Biopharma Inc. The current mfi is 56.07.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Theravance Biopharma Inc Daily Money Flow Index (MFI) ChartTheravance Biopharma Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Theravance Biopharma Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-06STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-11-07STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-08BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-11-13STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-16STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-17CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-20STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-21SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2023-11-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-24CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-30CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-01WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-05STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-08STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-11WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-12SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2023-12-15RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2023-12-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-17STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-18STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-31MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-01SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-14RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-02-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-16MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-20SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-23CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-04CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-13STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-25SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-27STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside

6.3. Candlestick Patterns

Theravance Biopharma Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Theravance Biopharma Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5051.472
Ma 20Greater thanMa 508.818
Ma 50Greater thanMa 1009.017
Ma 100Greater thanMa 2009.793
OpenGreater thanClose9.000
Total3/5 (60.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Theravance with someone you think should read this too:
  • Are you bullish or bearish on Theravance? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Theravance? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Theravance Biopharma Inc

I send you an email if I find something interesting about Theravance Biopharma Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Theravance Biopharma Inc.

Receive notifications about Theravance Biopharma Inc in your mailbox!